The AstraZeneca PLC ADR AZN slid 2.83% to $64.87 Thursday, on what proved to be an all-around poor trading session for the ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

The AstraZeneca PLC ADR AZN slid 3.90% to $65.79 Monday, on what proved to be an all-around mixed trading session for the ...

WILMINGTON, Del., March 31, 2025--AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here are the latest forecasts. When investing, your capital is at risk.

(Alliance News) - AstraZeneca PLC on Friday said it will establish a new global strategic research & development centre in Beijing. The Cambridge, England-based pharmaceutical company said it will ...

In its fourth quarter 2024 investor letter, Parnassus Growth Equity Fund emphasized stocks such as AstraZeneca PLC (NASDAQ:AZN). AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...